Molecular analysis and intestinal expression of SAR1 genes and proteins in Anderson's disease (Chylomicron retention disease)

Orphanet Journal of Rare Diseases

Volumn 6, Issue 1, 2011, Pages

  Georges, Amandine ^a   Bonneau, Jessica ^b   Bonnefont Rousselot, Dominique ^c   Champigneulle, Jacqueline ^d   Rabès, Jean P ^b,e   Abifadel, Marianne ^b   Aparicio, Thomas ^d   Guenedet, Jean C ^d,f   Bruckert, Eric ^e   Boileau, Catherine ^b,e   Morali, Alain ^a   Varret, Mathilde ^b   Aggerbeck, Lawrence P ^b   Samson Bouma, Marie E ^b  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b INSERM   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d UNIVERSITÉ PARIS 13   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f CHU NANCY BRABOIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIBODY; ARGININE; ASPARTIC ACID; GUANOSINE TRIPHOSPHATASE; KEXIN; LEUCINE; MEMBRANE PROTEIN; PANCREAS ENZYME; PROTEIN; PROTEIN PCSK9; PROTEIN SAR1; PROTEIN SAR1A; PROTEIN SAR1B; PROTEIN SERINE KINASE; RECOMBINANT PROTEIN; RECOMBINANT SAR1 PROTEIN; THREONINE; TOCOFERSOLAN; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN K GROUP; MONOMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; PCSK9 PROTEIN, HUMAN; SAR1A PROTEIN, HUMAN; SAR1B PROTEIN, HUMAN; SERINE PROTEINASE;

ADULT; AMINO ACID SUBSTITUTION; ANDERSON DISEASE; ARTICLE; CASE REPORT; CHILD; CHYLOMICRON RETENTION DISEASE; CONTROLLED STUDY; DUODENUM BIOPSY; FAMILIAL HYPOBETALIPOPROTEINEMIA; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC DISORDER; GENETIC VARIABILITY; HUMAN; IMMUNOHISTOCHEMISTRY; INFANT; INTESTINE; INTESTINE BIOPSY; INTESTINE CELL; LABORATORY TEST; LIPID DIET; MALABSORPTION; MALE; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PRESCHOOL CHILD; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; VITAMIN SUPPLEMENTATION; ADOLESCENT; EXON; GENETICS; HYPOBETALIPOPROTEINEMIA; METABOLISM; MUTATION;

ADOLESCENT; CHILD; EXONS; FEMALE; HUMANS; HYPOBETALIPOPROTEINEMIAS; IMMUNOHISTOCHEMISTRY; INTESTINES; MALABSORPTION SYNDROMES; MALE; MONOMERIC GTP-BINDING PROTEINS; MUTATION; SERINE ENDOPEPTIDASES;

EID: 78651364798     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-6-1     Document Type: Article

References (83)

1. Unusual causes of steatorrhoea in infancy and childhood. CM Anderson RRW Townley M Freeman P Johansen, Med J Australia 1961 ii 617 622
2. Maladie d'Anderson. C Polonovski J Navarro JL Fontaine F de Gouyon JM Saudubray L Cathelineau, Ann Pediatr 1970 17 342 354
3. Maladie d'Anderson. J Costil, Journées Parisiennes de Pédiatrie Flammarion Editeurs Paris 1976 229 239
4. Hypobetalipoproteinemia - a variant of the Bassen-Kornzweig syndrome. BB Scott JP Miller MS Losowski, Gut 1979 20 163 168 10.1136/gut.20.2.163 428829
5. Action tremor as a manifestation of chylomicron retention disease. S Gauthier A Sniderman, Ann Neurol 1983 14 591 10.1002/ana.410140517 6651243
6. Hypobetalipoproteinemia with accumulation of an apoprotein B-like protein in intestinal cells. ME Bouma I Beucler LP Aggerbeck R Infante J Schmitz, J Clin Invest 1986 78 398 410 10.1172/JCI112590 2426307
7. Anderson's disease. I Polenco MJ Mellado R Lama J Larrauri A Zapata E Redondo C Vazquez, An Esp Pediatr 1986 24 185 188 3706925
8. Malabsorption, hypocholesterolemia and fat-filled enterocytes with increased intestinal apoprotein B. CC Roy E Levy PHR Green A Sniderman J Letartre JP Buts J Orquin P Brochu AM Weber CL Morin,, et al. Gastroenterology 1987 92 390 399 3792776
9. Intestinal apoB synthesis, lipids, and lipoproteins in chylomicron retention disease. E Levy Y Marcel RJ Deckelbaum R Milne G Lepage E Seidman M Bendayan CC Roy, J Lipid Res 1987 28 1263 1274 3430059
10. Anderson's disease. Clinical and morphologic study of 7 cases. F Lacaille M Bratos ME Bouma J Jos J Schmitz J Rey, Arch Fr Pediatr 1989 46 491 498 2596948
11. Anderson's disease : no linkage to the apo B locus. D Strich R Goldstein A Phillips R Shemer Y Goldberg A Razin S Freier, J Pediatr Gastroenterol Nutr 1993 16 257 264 10.1097/00005176-199304000-00006 8492252
12. Studies on lipoprotein metabolism in a family with jejunal chylomicron retention. A Nemeth U Myrdal B Veress M Rudling L Berglund B Angelin, Eur J Clin Invest 1995 25 271 280 10.1111/j.1365-2362.1995.tb01559.x 7601203
13. Anderson's disease (steatorrhea due to the retention of chylomicrons) : diagnostic criteria. MO Benavent MC Casanova AP Perez CR Konickx JF Calvete, An Esp Pediatr 1997 47 195 198 9382356
14. Anderson's disease : exclusion of apolipoprotein and intracellular lipid transport genes. AH Dannoura N Berriot-Varoqueaux P Amati V Abadie N Verthier J Schmitz JR Wetterau ME Samson-Bouma LP Aggerbeck, Arterioscler Thromb Vasc Biol 1999 19 2494 2508 10521380
15. Vitamin E deficiency due to chylomicron retention disease in Marinesco-Sjogren syndrome. U Aguglia G Annesi G Pasquinelli P Spadafora A Gambardella F Annesi AA Pasqua F Cavalcanti L Crescibene A Bagala,, et al. Ann Neurol 2000 47 260 264 10.1002/1531-8249(200002)47:2<260::AID-ANA21>3.0. CO;2-V 10665502
16. Celiac disease or chylomicron retention disease? R Biselli R Boldrini M D'Altilia C Bosman, Pathologica 2000 92 130 10838886
17. Chylomicron retention disease - the role of ultrastructural examination in differential diagnosis. R Boldrini R Biselli C Bosman, Pathol Res Pract 2001 197 753 757 11770019
18. Mutations in a Sar1 GTPase of COPII vesicles are associated with lipid absorption disorders. B Jones EL Jones SA Bonney HN Patel AR Mensenkamp S Eichenbaum-Voline M Rudling U Myrdal G Annesi S Naik,, et al. Nat Genet 2003 34 29 31 10.1038/ng1145 12692552
19. Anderson or chylomicron retention disease: molecular impact of five mutations in the SAR1B gene on the structure and the functionality of Sar1b protein. M Charcosset A Sassolas N Peretti CC Roy C Deslandres D Sinnett E Levy A Lachaux, Mol Genet Metab 2008 93 74 84 10.1016/j.ymgme.2007.08.120 17945526
20. SIL1 and SARA2 mutations in Marinesco-Sjogren and chylomicron retention diseases. G Annesi U Aguglia P Tarantino F Annesi EV De Marco D Civitelli A Torroni A Quattrone, Clin Genet 2007 71 288 289 10.1111/j.1399-0004.2007.00759.x 17309654
21. Anderson's disease (chylomicron retention disease): a new mutation in the SARA2 gene associated with muscular and cardiac abnormalities. M Silvain D Bligny T Aparicio P Laforet A Grodet N Peretti D Menard F Djouadi C Jardel J Begue,, et al. Clin Genet 2008 74 546 552 10.1111/j.1399-0004.2008.01069.x 18786134
22. Novel missense mutations of SAR1B gene in an infant with chylomicron retention disease. S Treepongkaruna N Chongviriyaphan U Suthutvoravut D Charoenpipop L Choubtum D Wattanasirichaigoon, J Pediatr Gastroenterol Nutr 2009 48 370 373 10.1097/MPG.0b013e318183188f 19274794
23. Variable phenotypic expression of chylomicron retention disease in a kindred carrying a mutation of the Sara2 gene. AB Cefalu PL Calvo D Noto M Baldi V Valenti P Lerro F Tramuto A Lezo I Morra G Cenacchi,, et al. Metabolism 2010 59 463 467 10.1016/j.metabol.2009.07.042 19846172
24. Chylomicron retention disease: a long term study of two cohorts. N Peretti CC Roy A Sassolas C Deslandres E Drouin A Rasquin E Seidman P Brochu MC Vohl S Labarge,, et al. Mol Genet Metab 2009 97 136 142 10.1016/j.ymgme.2009.02. 003 19285442
25. Chylomicron retention disease: dystonia as a new clinical feature. G Bernard M Panisset AF Sadikot S Chouinard, Mov Disord 2010 25 1755 1756 10.1002/mds.23165 20589877
26. Guidelines for the diagnosis and management of chylomicron retention disease based on a review of the literature and the experience of two centers. N Peretti A Sassolas CC Roy C Deslandres M Charcosset J Castagnetti L Pugnet-Chardon P Moulin S Labarge L Bouthillier A Lachaux E Levy, Orphanet Journal of Rare Diseases 2010 5 24 10.1186/1750-1172-5-24 20920215
27. The COPII cage: unifying principles of vesicle coat assembly. C Gurkan SM Stagg P Lapointe WE Balch, Nat Rev Mol Cell Biol 2006 7 727 738 10.1038/nrm2025 16990852
28. Coordination of COPII vesicle trafficking by Sec23. JC Fromme L Orci R Schekman, Trends Cell Biol 2008 18 330 336 10.1016/j.tcb.2008.04.006 18534853
29. Structural basis for cargo regulation of COPII coat assembly. SM Stagg P LaPointe A Razvi C Gurkan CS Potter B Carragher WE Balch, Cell 2008 134 474 484 10.1016/j.cell.2008.06.024 18692470
30. Assembly, organization, and function of the COPII coat. H Hughes DJ Stephens, Histochem Cell Biol 2008 129 129 151 10.1007/s00418-007-0363-x 18060556
31. COPII proteins are required for Golgi fusion but not for endoplasmic reticulum budding of the pre-chylomicron transport vesicle. SA Siddiqi FS Gorelick JT Mahan CM Mansbach, J Cell Sci 2003 116 415 427 10.1242/jcs.00215 12482926
32. Liver fatty acid-binding protein initiates budding of pre-chylomicron transport vesicles from intestinal endoplasmic reticulum. I Neeli SA Siddiqi S Siddiqi J Mahan WS Lagakos B Binas T Gheyi J Storch CM Mansbach, J Biol Chem 2007 282 17974 17984 10.1074/jbc.M610765200 17449472
33. A Novel Multi-protein Complex Is Required for the Generation of the Pre-chylomicron Transport Vesicle from Intestinal ER. S Siddiqi U Saleem N Abumrad N Davidson J Storch SA Siddiqi CM Mansbach, J Lipid Res 2010 51 1918 1928 10.1194/jlr.M005611 20237389
34. Sec24C is required for docking the prechylomicron transport vesicle with the Golgi. S Siddiqi SA Siddiqi CM Mansbach, J Lipid Res 2010 51 1093 1100 10.1194/jlr.M002758 19965600
35. The biogenesis of chylomicrons. CM Mansbach SA Siddiqi, Annu Rev Physiol 2010 72 315 333 10.1146/annurev-physiol-021909-135801 20148678
36. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. M Abifadel M Varret JP Rabes D Allard K Ouguerram M Devillers C Cruaud S Benjannet L Wickham D Erlich,, et al. Nat Genet 2003 34 154 156 10.1038/ng1161 12730697 (Pubitemid 36666925)
37. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. M Abifadel JP Rabes M Devillers A Munnich D Erlich C Junien M Varret C Boileau, Hum Mutat 2009 30 520 529 10.1002/humu.20882 19191301
38. PCSK9: a convertase that coordinates LDL catabolism. JD Horton JC Cohen HH Hobbs, J Lipid Res 2009 50 Suppl 172 7 10.1194/jlr.R800091-JLR200 19020338
39. Molecular basis of PCSK9 function. G Lambert F Charlton KA Rye DE Piper, Atherosclerosis 2009 203 1 7 10.1016/j.atherosclerosis.2008.06.010 18649882
40. Enzymatic determination of total serum cholesterol. CC Allain LS Poon CS Chan W Richmond PC Fu, Clin Chem 1974 20 470 475 4818200
41. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. P Fossati L Prencipe, Clin Chem 1982 28 2077 2080 6812986
42. Multicenter evaluation on different analyzers of three methods for direct HDL-cholesterol assay. M Egloff D Leglise L Duvillard J Steinmetz MJ Boyer A Ruelland R Agher I Beucler, Ann Biol Clin (Paris) 1999 57 561 572 10518058
43. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. WT Friedewald RI Levy DS Fredrickson, Clin Chem 1972 18 499 502 4337382
44. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. II. Evaluation and selection of candidate reference materials. JJ Albers SM Marcovina H Kennedy, Clin Chem 1992 38 658 662 1582016
45. Monoclonal antibodies to low density lipoprotein used for the study of low- and very-low-density lipoproteins, in "ELISA" and immunoprecipitation technics. S Salmon S Goldstein D Pastier L Theron M Berthelier M Ayrault-Jarrier M Dubarry R Rebourcet B Pau, Biochem Biophys Res Commun 1984 125 704 711 10.1016/0006-291X(84)90596-5 6083790
46. Use of bacterial expression cloning to localize the epitopes for a series of monoclonal antibodies against apolipoprotein B-100. RJ Pease RW Milne WK Jessup A Law P Provost JC Fruchart P Roevens, J Biol Chem 1990 265 553 568 1688435
47. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. KJ Livak TD Schmittgen, Methods 2001 25 402 408 10.1006/meth.2001.1262 11846609
48. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. JR Patsch G Miesenbock T Hopferwieser V Muhlberger E Knapp JK Dunn AM Gotto Jr W Patsch, Arterioscler Thromb 1992 12 1336 1345 1420093
49. The c.43-44insCTG variation in PCSK9 is associated with low plasma LDL-cholesterol in a Caucasian population. P Yue M Averna X Lin G Schonfeld, Hum Mutat 2006 27 460 466 10.1002/humu.20316 16619215
50. A gene atlas of the mouse and human protein-encoding transcriptomes. AI Su T Wiltshire S Batalov H Lapp KA Ching D Block J Zhang R Soden M Hayakawa G Kreiman,, et al. Proc Natl Acad Sci USA 2004 101 6062 6067 10.1073/pnas. 0400782101 15075390
51. Large-scale profiling of Rab GTPase trafficking networks: the membrome. C Gurkan H Lapp C Alory AI Su JB Hogenesch WE Balch, Mol Biol Cell 2005 16 3847 3864 10.1091/mbc.E05-01-0062 15944222
52. Expression of Sara2 human gene in erythroid progenitors. DL Jardim AF da Cunha S Duarte Ada CO dos Santos ST Saad FF Costa, J Biochem Mol Biol 2005 38 328 333 15943909
53. Mutations affecting the secretory COPII coat component SEC23B cause congenital dyserythropoietic anemia type II. K Schwarz A Iolascon F Verissimo NS Trede W Horsley W Chen BH Paw KP Hopfner K Holzmann R Russo,, et al. Nat Genet 2009 41 936 940 10.1038/ng.405 19561605
54. The role of the Microsomal Triglyceride Transfer Protein in Abetalipoproteinemia. N Berriot-Varoqueaux LP Aggerbeck ME Samson-Bouma JR Wetterau, Annu Rev Nutr 2000 20 663 697 10.1146/annurev.nutr.20.1.663 10940349
55. Decreased fluidity of red cell membrane lipids in abetalipoproteinemia. RA Cooper JR Durocher MH Leslie, J Clin Invest 1977 60 115 121 10.1172/JCI108747 874076
56. L'absence congénital de beta-lipoprotéines: étude de l'absorption des graisses après exsanguino-transfusion et mesure de la demi-vie des betalipoprotéines injectées. J Frézal J Rey J Polonovski G Levy M Lamy, Rev Fr Clin Biol 1961 6 677 683 13701866
57. The relationship between serum lipoproteins and red cell membranes in abetalipoproteinemia and deficiency of lecithin cholesterol acyl transferase. RA Cooper CL Gulbrandsen, J Lab Clin Med 1971 78 323 335 5092855
58. Bassen-Kornzweig syndrome: Deficiency of serum -Lipoprotein: A neuromuscular disorder resembling Friedreich's Ataxia, associated with steatorrhea, acanthocytosis, retinitis pigmentosa, and a disorder of lipid metabolism. JF Schwartz LP Rowland H Eder PA Marks EF Osterman E Hirschberg H Anderson, Arch Neurol 1963 8 438 454
59. Acanthocytes and hypocholesterolemia. J Perrin A Georges A Morali C Vigneron T Lecompte JF Lesesve, Ann Biol Clin Paris 2008 66 569 572 18957348
60. Sar1-GTPase-dependent ER exit of KATP channels revealed by a mutation causing congenital hyperinsulinism. TK Taneja J Mankouri R Karnik S Kannan AJ Smith T Munsey HB Christesen DJ Beech A Sivaprasadarao, Hum Mol Genet 2009 18 2400 2413 10.1093/hmg/ddp179 19357197
61. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. S Rashid DE Curtis R Garuti NN Anderson Y Bashmakov YK Ho RE Hammer YA Moon JD Horton, Proc Natl Acad Sci USA 2005 102 5374 5379 10.1073/pnas.0501652102 15805190
62. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. DW Zhang TA Lagace R Garuti Z Zhao M McDonald JD Horton JC Cohen HH Hobbs, J Biol Chem 2007 282 18602 18612 10.1074/jbc.M702027200 17452316
63. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Z Zhao Y Tuakli-Wosornu TA Lagace L Kinch NV Grishin JD Horton JC Cohen HH Hobbs, Am J Hum Genet 2006 79 514 523 10.1086/507488 16909389
64. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. AJ Hooper AD Marais DM Tanyanyiwa JR Burnett, Atherosclerosis 2007 193 445 448 10.1016/j.atherosclerosis.2006.08.039 16989838
65. Identification of mutations in the apolipoprotein B-100 gene and in the PCSK9 gene as the cause of hypocholesterolemia. TP Leren KE Berge, Clin Chim Acta 2008 397 92 95 10.1016/j.cca.2008.07.025 18710658
66. New insights into the structural mechanisms of the COPII coat. C Russell SM Stagg, Traffic 2010 11 303 310 10.1111/j.1600-0854.2009.01026.x 20070605
67. PKC zeta-mediated phosphorylation controls budding of the pre-chylomicron transport vesicle. SA Siddiqi CM Mansbach, J Cell Sci 2008 121 2327 2338 10.1242/jcs.022780 18577579
68. Protection against Western diet-induced obesity and hepatic steatosis in liver fatty acid-binding protein knockout mice. EP Newberry Y Xie SM Kennedy J Luo NO Davidson, Hepatology 2006 44 1191 1205 10.1002/hep.21369 17058218
69. Diet-induced alterations in intestinal and extrahepatic lipid metabolism in liver fatty acid binding protein knockout mice. EP Newberry SM Kennedy Y Xie J Luo NO Davidson, Mol Cell Biochem 2009 326 79 86 10.1007/s11010-008-0002-4 19116776
70. Vesicle-associated membrane protein 7 is expressed in intestinal ER. SA Siddiqi J Mahan S Siddiqi FS Gorelick CM Mansbach, J Cell Sci 2006 119 943 950 10.1242/jcs.02803 16495485
71. The identification of a novel endoplasmic reticulum to Golgi SNARE complex used by the prechylomicron transport vesicle. SA Siddiqi S Siddiqi J Mahan K Peggs FS Gorelick CM Mansbach, J Biol Chem 2006 281 20974 20982 10.1074/jbc.M601401200 16735505
72. Cranio-lenticulo-sutural dysplasia is caused by a SEC23A mutation leading to abnormal endoplasmic-reticulum-to-Golgi trafficking. SA Boyadjiev JC Fromme J Ben SS Chong C Nauta DJ Hur G Zhang S Hamamoto R Schekman M Ravazzola,, et al. Nat Genet 2006 38 1192 1197 10.1038/ng1876 16980979
73. The genetic basis of a craniofacial disease provides insight into COPII coat assembly. JC Fromme M Ravazzola S Hamamoto M Al-Balwi W Eyaid SA Boyadjiev P Cosson R Schekman L Orci, Dev Cell 2007 13 623 634 10.1016/j.devcel.2007.10. 005 17981132
74. Sec24b selectively sorts Vangl2 to regulate planar cell polarity during neural tube closure. J Merte D Jensen K Wright S Sarsfield Y Wang R Schekman DD Ginty, Nat Cell Biol 2010 12 41 46 sup pp 1-8 10.1038/ncb2002 19966784
75. COPII-coated vesicles: flexible enough for large cargo? JC Fromme R Schekman, Curr Opin Cell Biol 2005 17 345 352 10.1016/j.ceb.2005.06.004 15975775
76. VLDL exits from the endoplasmic reticulum in a specialized vesicle, the VLDL transport vesicle, in rat primary hepatocytes. SA Siddiqi, Biochem J 2008 413 333 342 10.1042/BJ20071469 18397176
77. The Identification of the SNARE-complex Required for the Fusion of VLDL Transport Vesicle with Hepatic cis-Golgi. S Siddiqi AM Mani SA Siddiqi, Biochem J 2010 429 391 401 10.1042/BJ20100336 20450495
78. Apolipoprotein B100 exit from the endoplasmic reticulum (ER) is COPII-dependent, and its lipidation to very low density lipoprotein occurs post-ER. V Gusarova JL Brodsky EA Fisher, J Biol Chem 2003 278 48051 48058 10.1074/jbc.M306898200 12960170
79. Decreased expression of Intestinal I- and L-FABP levels in rare human genetic lipid malabsorption syndromes. S Guilmeau I Niot JP Laigneau H Devaud V Petit N Brousse R Bouvier L Ferkdadji C Besmond LP Aggerbeck,, et al. Histochem Cell Biol 2007 128 115 123 10.1007/s00418-007-0302-x 17605029
80. Multiple levels of control of the stage- and region-specific expression of rat intestinal lactase. I Duluc B Jost JN Freund, J Cell Biol 1993 123 1577 1586 10.1083/jcb.123.6.1577 8253852
81. Mosaic regulation of lactase in human adult-type hypolactasia. L Maiuri M Rossi V Raia V Garipoli LA Hughes D Swallow O Noren H Sjostrom S Auricchio, Gastroenterology 1994 107 54 60 8020689
82. Genetic mosaic analysis based on Cre recombinase and navigated laser capture microdissection. MH Wong JR Saam TS Stappenbeck CH Rexer JI Gordon, Proc Natl Acad Sci USA 2000 97 12601 12606 10.1073/pnas.230237997 11050178
83. Cellular differentiation in the emerging fetal rat small intestinal epithelium: mosaic patterns of gene expression. DC Rubin DE Ong JI Gordon, Proc Natl Acad Sci USA 1989 86 1278 1282 10.1073/pnas.86.4.1278 2645578